- September, 2011
Countervail Corporation is awarded a $5.3 million contract by the Biomedical Advanced Research and Development Authority - September, 2010
Countervail corporation is awarded $346,000 for phase 1 of fast track SBIR Grant from the National Institutes of Health for studies of nerve gas antidote - September, 2010
New Charlotte, NC office opened at the Ben Craig Center Business Incubator - April, 2009
Countervail's principal investigator presents at 2009 NINDS CounterACT meeting in Washington, DC. Dr. Edson Albuquerque presents additional data on galantamine's effectiveness in preserving survival and prevention of neural cell damage from nerve agent exposure. - April, 2009
Countervail wins business plan competition at 8th annual Five Ventures conference. Out of 130 competing companies, Countervail wins the Biotechnology - Pharmaceutical division for best business plan presentation. - February, 2009
Pre-IND FDA Meeting Held. - June, 2008
Countervail Corporation awarded $25,000 in matching business development funding from the NC BioTech Center in support of FDA Pre-IND activities for product commercialization. - April, 2008
Meetings and Presentation at 2nd Annual CounterACT Network Research Symposium
(Countermeasures against Chemical Threats)
Meetings and Presentation at North Carolina Venture Capital Symposium - March, 2008
Presentation at New Jersey Economic Development Council
Presentation at New Jersey Technical Council - October, 2007
Pre-IND Committee Discussion and Presentation (FDA, NIH , DOD and BARDA) - August, 2007
Initial Seed Financing secured - July, 2007
Master License Agreement Signed with University of Maryland Baltimore - June, 2007
Countervail Incorporated
Home | About Us | Galantamine | Investors | Contact | Sitemap
Copyright © 2012, Countervail Corporation.
Design Solutions by: Optime Productions
Copyright © 2012, Countervail Corporation.
Design Solutions by: Optime Productions